Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Presenting at Upcoming Healthcare Conferences
TUCSON, Ariz. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that TJ Johnson, Chief Executive Officer, will present a corporate overview the Canaccord
Toggle Summary HTG Molecular Diagnostics Reports Third Quarter 2018 Results
Revenue increased 26% and 101% for the three and nine months ended September 30, 2018 compared to the respective prior year periods Call scheduled for today, November 8 , at 4:30 pm ET TUCSON, Ariz. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
Toggle Summary HTG Molecular Appoints Dr. Maureen T. Cronin as Chief Scientific Officer and Senior Vice President
TUCSON, Ariz. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM)  (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced the appointment of Maureen T. Cronin , Ph.D., as the Company’s Chief Scientific Officer
Toggle Summary HTG Molecular Diagnostics to Announce Third Quarter and Nine Months Ended September 30, 2018 Financial Results and Host Conference Call on Thursday, November 8
TUCSON, Ariz. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it will report its financial results for the three and nine months ended September 30, 2018
Toggle Summary HTG Molecular Diagnostics Announces the Institute of Oncology Research Has Adopted the HTG EdgeSeq Technology in its Genomics Facility
HTG’s extraction-free, targeted next-generation sequencing technology adopted to support the IOR’s research and clinical trials in hematological cancers and solid tumors TUCSON, Ariz. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (“HTG”), a provider of

Stock Chart

SEC Filings

Filing date Description

Report of unscheduled material events or corporate event

Quarterly report which provides a continuing view of a company's financial position

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities